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Abstract
Background: This study is a systematic review and meta-analysis of the diagnostic value of cardiovascular magnetic
resonance (CMR) in cardiac amyloidosis (CA).
Methods: A wide variety of electronic databases were searched for studies of CMR that reported the diagnostic
accuracy in patients with suspected CA. Research manuscripts were subjected to further systematic review and
meta-analysis. Methodological evaluation was performed under the guidance of the Quality Assessment of
Diagnostic Accuracy Studies −2 (QUADAS–2). Heterogeneity was assessed, and a random-effects model was used to
assess the diagnostic effects of CMR on pooled sensitivity, pooled specificity, and summary receiver operating
characteristics (SROC).
Results: Seven studies that reported the performance of CMR for CA were included in the present systematic
review, among which five studies (257 patients) that evaluated the diagnostic accuracy of late gadolinium
enhancement (LGE) CMR were analyzed in the present meta-analysis. Heterogeneity was observed only in
specificity. A summary sensitivity and specificity of 85 % (95 % CI: 77–91 %) and 92 % (95 % CI: 83–97 %) indicated
a high diagnostic accuracy of LGE for CA. The AUC of SROC curve was 0.9530, suggesting that LGE is an effective
way of diagnosing patients with possible cardiac involvement in amyloidosis.
Conclusions: LGE–CMR seems to have a relatively high diagnostic accuracy for amyloidosis patients with possible
cardiac involvement. Combined CMR techniques may provide important information for the selection of suitable
therapy.
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Background
The heart, like any organ in the body is susceptible to
amyloid deposition. When this occurs in the heart, car-
diac amyloidosis (CA) results. Although more than 30
types of protein can cause amyloid, only two types com-
monly deposit in the ventricular myocardium: amyloid
light chain (AL) and amyloid transthyretin (ATTR). The
heart is sometimes the only or early manifestation of sys-
temic amyloidosis [1]. Deposition of amyloid precursor
proteins which then aggregate into amyloid fibrils in the
extracellular space causes separation and distortion of the
existing tissues and eventually causes irreversible cardiac
dysfunction [2, 3]. This may occur in the myocardium,
pericardium, small vessels and conduction system. The re-
sult is a restrictive cardiomyopathy with early diastolic
dysfunction and later systolic dysfunction, conduction dis-
ease including sudden death and, occasionally ischaemia
(with arterial involvement) [4].
CA is relatively under-diagnosed, especially wild type
ATTR in older people with multisystem diseases. One
potential reason is that the symptoms and signs of CA
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such as fatigue, low exercise tolerance and occasionally
syncope with progressive diastolic and systolic dysfunc-
tion may be nonspecific, particularly in the early phases,
resulting in delayed diagnosis and potentially missed
therapeutic options. New treatments are available target-
ing the precursor proteins, including newer chemother-
apy regimes and a variety of approaches to reduce
transthyretin as a precursor, with further developments
in the preclinical phase [5, 6]. For this reason, earlier
diagnosis of CA is a major clinical goal [7].
Currently, the main steps in the clinical evaluation of
patients with CA involve suspicion, detection, and classi-
fication. Suspicion may be raised by multisystem in-
volvement (carpal tunnel, renal impairment etc.).
Laboratory investigations may confirm the diagnosis,
classify the CA, trace the specific protein precursor and
appraise the stage of cardiac involvement including
pump function [8]. Currently, the most common exam-
ination procedures used to evaluate patients or condi-
tions associated with CA include endomyocardial biopsy
(EMB), electrocardiography (ECG), echocardiography
and cardiac magnetic resonance (CMR) with some nu-
clear tests contributing (bone scintigraphy for ATTR,
SAP scan for AL - but these are not widely available).
In CA, myocardial tissue histology stands as the gold
standard, revealing the accumulation of amyloid proteins
and fibers in the extracellular space. Histologically, EMB
is initially stained using Congo Red where deposits may
look pale red but show apple-green birefringence under
cross-polarized light. Immunohistochemistry (IHC) or
mass-spectrocopy can definitively subtype the amyloid
fibrils [4]. However, the invasive nature of EMB and re-
lated high-risk complications are barriers, as is the spe-
cialist nature of IHC and mass spectroscopy. Besides, as
the lack of standardization on the definition of what
constitutes CA, in some cases these is a need to use
some ancillary imaging and clinical findings to ensure
the pathological diagnosis. In addition, EMB is classified
in the class IIa recommendation [9].
ECG Low -voltages is a classical feature of CA [10]. But
it provides a low -sensitivity and -specificity diagnosis of
CA. This may be due in part to interference from other
coexisting conditions, such as obesity, hypothyroidism,
and pulmonary diseases, but up to 25 % of ATTR subjects
have left ventricular hypertrophy. Under echocardiograph,
the CA classical feature (a "brilliant" speckled appearance
of myocardium) is a poor discriminator. Biventricular
hypertrophy with disproportionate long axis impairment
and restriction is more specific, but still has overlap, par-
ticularly in early disease [11].
CMR, a noninvasive mean of assessing amyloid bur-
den, makes use of a superconducting magnet with
ECG gating to measure the structure and function of
the heart analogous to echocardiography. In addition,
myocardial tissue characterisation detects tissue path-
ology [12]. In particular, the late gadolinium enhance-
ment (LGE) has a characteristic pattern in amyloid
with subendocardial, later transmural LGE and diffi-
culty nulling. This latter issue appears resolved with
the phase-sensitive inversion recovery (PSIR) LGE se-
quence and it has potential to be a key technique for
the diagnosis of patients with potential CA [13]. Sev-
eral studies have compared the diagnostic accuracy of
CMR to that of EMB. However, they focused on dif-
ferent parameters and used different cutoff values in
diagnostic tests, which limit their usefulness in the
assessment of CA. For this reason, a systematic re-
view was conducted to help evaluate the diagnostic
aspects of CMR in patients with suspected CA.
Methods
Data sources
This systematic review was carried out under the guide-
line of the Cochrane Collaboration’s Diagnostic Test Ac-
curacy Group. Search strategies were developed to
identify all the relevant studies published in the Pubmed,
Embase, the Cochrane Library, Biosis Preview, ISI Web
of Science, and China National Knowledge Infrastruc-
ture up to April 20, 2015. Medical subject headings and
full text were searched for references to CA and mag-
netic resonance imaging to systematically locate these
publications in any language. The details of the search
strategies are provided in the additional files. The cita-
tions of eligible publications and reviews were also
checked. Requirements were limited to human trials.
Study selection and data collection
The first author (LZ) conducted the initial literature
search of titles and abstracts. Upon further scrutiny, two
reviewers (LZ, ZT) led the retrieval of the full texts of
relevant manuscripts independently. A third reviewer
(QF) resolved all the disagreements and discrepancies
that occurred during these processes through deep dis-
cussions. The following inclusion criteria were defined
in advance: (1) a diagnostic accuracy test was included;
(2) patients with at least suspected CA; (3) the diagnos-
tic accuracy of CMR was evaluated regardless of acquisi-
tion protocol used; (4) EMB, clinical criteria, or both
served as the reference tests; (5) the absolute numbers
of true positive, false positive, true negative, and false
negative results could be derived. All the articles that met
these criteria were considered eligible. Duplicate and over-
lapping publications were excluded. Conference abstracts
and research manuscripts that could not be obtained in
their entirety or from which essential information was
missing were also excluded. Diagnostic accuracy details,
study methods, results, and additional information on
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patients and procedures were extracted from each primary
study independently by two reviewers (LZ, ZT).
Assessment of risk of bias
Two reviewers (LZ, ZT) appraised the methodological
quality based on the form suggested by the Quality As-
sessment of Diagnostic Accuracy Studies–2 (QUADAS–
2), which has main parts: patient selection, index test, ref-
erence standards, and the flow and timing [14]. Each part
involves the assessment of risk of bias (low, high, or un-
clear) and first 3 parts also need to evaluate the clinical
applicability. In cases of disagreement, 2 reviewers would
reach a consensus after a thorough discussion with a third
person (QF).
Statistical analysis
Statistical analyses were conducted using MetaDisc 1.4
software and Review Manager software version 5.3. First,
heterogeneity in included manuscripts was assessed in
terms of Cochran Q chi-square tests and I2 statistics. In
cases of significant heterogeneity, the random-effects
model was suitable to pool several parameters and
Fig. 1 Flow chart of selection process
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sensitivity analysis was used to investigate potential
sources targeting risk bias calculated by QUADAS–2. In
other cases, the Mantel-Haenszel method was used to
establish a fixed-effects model during the evaluation
process. In cases of implicit threshold effects, the Spear-
man rank correlation was taken into consideration. Sub-
group analysis determined if there was a correlation
between sensitivity and specificity. Second, positive like-
lihood ratios (PLR), negative likelihood ratios (NLR), and
diagnostic odds ratio (DOR), and their 95 % confidence
intervals (CI) were estimated based on pooled sensitivity
and specificity. In order to estimate the overall diagnos-
tic effect, a summary receiver operating characteristic
(SROC) curve was established, with pertinent areas.
Whenever a study’s data contained zero counts, 0.5 was
added as a continuity correction. Any significantly statis-
tical calculating was at a two-sided 0.05 level.
Results
The systematical electronic search identified 110 publi-
cations, of which 46, 32, 16, 10, 5, and 1 were found in
Pubmed, Biosis Preview, Embase, ISI Web of Science,
Cochrane Library and China National Knowledge Infra-
structure. Figure 1 outlines the process of manuscripts
screening. Here, 21 studies were excluded because of du-
plicate records. After the removal of 59 studies whose ti-
tles or abstracts did not meet the inclusion criteria, only
30 full-text articles were retained for further evaluation.
Of the 30 potentially appropriate publications, only 7
were included in the systematic review [15–21]. Most of
the excluded studies were reviews or did not provide ab-
solute figures. The meta-analysis was performed on 5
studies that focused on the LGE performance [17–21].
Methodological evaluation
Figure 2 shows the graphs of risk bias and concerns about
clinical application evaluated by QUADAS–2. In the
patient selection domain, one report did not state that pa-
tients were enrolled in a consecutive pattern [20]. Another
study lacked relevant information on patient sampling
[16]. The Karamitsos and Hosch studies both used a
case–control design [15]. In terms of an inappropriate ex-
clusion, both Karamitsos and Hosch’s studies were un-
clear. Regarding interpretation of the CMR results, 2
studies did not clearly state whether they were conducted
before knowing the results of EMB, the one by Karamitsos
and another one by Austin [19]. LGE–CMR was used in 6
studies, and one study used MR-relaxometry to evaluate
T1 and T2 relaxation time (RT), which established a cut-
off value of 1273 ms of T1-RT to diagnose CA with a high
sensitivity and specificity [15]. The other 6 studies detailed
the LGE-CMR procedures and defined amyloid LGE pat-
tern using long and short axes images in the ventricular
area without coronary artery distribution [16–21]. No
Fig. 2 Assessment of methodological quality according to QUADAS-2
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concerns about the included patients going against the
inclusion criteria.
There were 2 studies that did not clearly report
that the EMB evaluation was blinded to CMR results
[19, 21]. Another study stated it was done without
blindness [17]. In terms of the reference tests, some
patients could not be classified clearly using clinical
criteria alone [16, 21]. This kind of study involved
high risk bias and uncertainty regarding use in the
reference domain.
One study was discarded because of incomplete data for
2 × 2 table [16]. The interval between CMR and the refer-
ence test were only clearly stated in 3 studies [17, 19, 21].
But these 3 studies together did not use the same refer-
ence test on all the patients. Some patients were evaluated
by EMB and others were clinically assessed using ECG,
echocardiography, or both. In the study by White, only 25
(28 %) patients with suspected CA were included in the
final diagnostic evaluation [18].
Overall, all the included studies involved little con-
cerns regarding applicability and remaining 5 studies
were here considered methodologically correct regard-
less of risk bias [17–21].
Study characteristics
The baseline characteristics of these included studies are
shown in Table 1 [15–21]. A total of 485 subjects were
recruited in the final systematic analysis. These manu-
scripts were published during the period from 2007 to
2014 and four of them were prospective studies [15, 18,
20, 21]. Patients involved in individual studies are sum-
marized concisely in Table 1. The sample size ranged
from 28 to 106 and the mean age was similarly around
62 years old. Mean time intervals were only available in
three studies [17, 19, 21]. Six studies used EMB as a ref-
erence test [15, 17–21]. Another one used echocardiog-
raphy and clinical features as to classify patients [16]. All
studies used 1.5-T scanners to perform the CMR, but
Table 1 Characteristics of included studies
Study Year Country Study
design











2007 Germany PC 19 with newly
diagnosed CA and 9
patients with systemic
amyloidosis but
without CA and 10
healthy, age-matched
control
59 ± 6.1 14 NA Y EMB T1 and T2 RT 1.5 T
Vogelsberg
et al.
2008 Germany NA 33 subjects with
suspected CA





2009 USA RC 47 subjects with
suspected CA
62 33 24–48 h N EMB LGE; DHE 1.5 T
Ruberg
et al.
2009 USA PC 28 patients with
systemic AL
amyloidosis



































2014 USA PC 90 patients with
suspected CA and 64
hypertensive patients
with LVH
62 ± 13 52 NA Y EMB LGE pattern:
Global HE
1.5 T
AL amyloid light-chain, CA cardiac amyloidosis, DHE delayed hyper-enhancement, ECG echocardiography, HE hyperenhancement, EMB endomyocardial biopsy, LGE
late gadolinium enhancement, LVH left ventricular hypertrophy, N no, NA not available, PC prospective cohort, RC retrospective cohort, RT relaxation times, SID signal
intensity decay
aTime interval between reference tests and cardiac magnetic resonance
bThe CMR results were interpreted blind to the results of the reference tests or the reference tests were performed without knowing the results of cardiac
magnetic resonance
cAmyloid patients with definite cardiac involvement
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only five of them evaluated the diagnostic accuracy of
LGE by calculating sensitivity and specificity [17–21].
No adverse events were reported in the examinations.
Diagnostic performance of CMR for CA
Five studies contained absolute figures for 2 × 2 tables
with respect to LGE and were included in the meta-
analysis (Table 2) [17–21]. Individual studies are shown
on forest plots focusing on sensitivity and specificity.
The χ2 test for sensitivity and specificity produced a P
value of 0.2003 and 0.0581 with I2 values of 33.2 % and
56.1 %, respectively. In cases with a detectable threshold
effect, the Spearman rank correlation between the sensi-
tivity and 1-specifity was performed and the correlation
coefficient was 0.8 with a P value 0.104 (Additional files
1 and 2). Because the inconsistency index I2 was used to
quantify the heterogeneity, an I2 value of 56.1 % was
considered moderate (50–74 %). For this reason, the
random-effects model was used for the meta-analysis.
As shown in Fig. 3, the pooled sensitivity and specifi-
city of LGE-CMR were 85 % (95 % CI: 77–93 %) and
92 % (95 % CI: 83–97 %). The pooled positive likelihood
ratio was 7.481 (95 % CI: 2.835–19.739) and the negative
one was 0.183 (95% CI: 0.121–0.277). Figure 4 shows the
SROC curve for LEG-CMR, suggesting the LGE is an ef-
fective mean of diagnosing patients with amyloidosis
and potential cardiac involvement. These results also
corresponded to the pooled diagnostic odd ratio (Fig. 5).
There was some residual heterogeneity in the diagnostic
accuracy. Sensitivity analysis was conducted to deter-
mine the source of heterogeneity. After removing the
study by Aquaro which involved high risk bias in the
methodological evaluation, results showed the specificity
have an I2 value of 9.3 % and P value of 0.3467 [21].
However, this did not change the direction or magnitude
of the pooled estimates, which means that the results of
relatively good quality. Because only 5 publications were
included, no funnel plot was constructed to assess publi-
cation bias.
Discussion
Amyloidosis, when it affects the heart, has a poor progno-
sis. Better diagnostic tests would permit earlier detection
and therefore targeted intervention to improve outcomes.
Many modalities have been used in clinical settings to de-
tect and evaluate CA [22]. The most common methods
are ECG and echocardiography. These tools are conveni-
ent and available in most medical facilities in which the
EMB is not in common use. However, both methods de-
tect CA with a relatively low accuracy. ECG evaluation is
not suitable for patients with pulmonary disorders but
many patients with cardiomyopathy, especially elderly
patients, are likely to be involved in cardiopulmonary
diseases. Echocardiography can detect the advanced cases
[23]. However, it cannot easily assess earlier cases or dif-
ferentiate CA from hypertrophic cardiomyopathy because
the characteristics in echocardiography are thick-walled
ventricles with speckled myocardia [4, 23]. EMB is consid-
ered the gold standard in the diagnosis of CA. However,
the unavailability, relatively high risks and clinical compli-
cations may hinder its widespread use in clinical settings.
CMR provides a third option in the evaluation of the
heart’s structure and assessment of its diastolic function.
It is more precise and more accurate, which are regarded
as the hallmarks of good non-invasive methods capable of
assessing myocardial scars [13, 24].
The key advantage of using CMR to detect the CA is
its unique ability to describe the characteristics of heart,
which can be done particularly using LGE [25]. After
taking the gadolinium-based contrast, patients with CA
presented typical global subendocardial enhancement
patterns, which are closely associated with interstitial
amyloid burden and often used to qualitatively detect
focal fibrosis [26]. This meta-analysis of LGE–CMR
Table 2 Cardiac magnetic resonance evaluation of the included studies in the systematic review
Study Number of subjects Index measured using CMR TF FP FN TN Sensitivity (%) Specificity (%) PPV (%) NPV (%) AUC
Hosch et al. 38 T1-RT 16a 0a 3a 10a 84a 100a NAa NAa 0.96a
16b 1b 3b 8b 84b 89b NAb NAb 0.89b
Vogelsberg et al. 33 LGE 12 1 3 17 80 94 92 85 NA
Austin et al. 47 LGE 15 2 2 19 88 90 88 90 NA
Ruberg et al. 28 LGE 18 1 3 6 86 86 95 67 NA
Karamitsos et al. 106 Noncontrast T1 mapping 36 6 3 61 92 91 NA NA NA
Aquaro et al. 79 SID 51 2 1 26 98 93 96 96 NA
LGE 42 0 10 27 81 100 100 73 NA
White et al. 154 LGE 15 3 0 7 93 70 NA NA NA
AUC area under receiver-operating characteristic curve, FN false negative, FP false positive, TN true negative, TP true positive, PPV positive predictive value, NA not
available, NPV negative predictive value, LGE late gadolinium enhancement, RT relaxation time, SID signal intensity decay
aCA patients compared with the healthy, age-matched control group
bCA patients compared with the patient group with systemic amyloidosis but without cardiac involvement
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Fig. 3 Forest plot evaluating the sensitivity and specificity of diagnostic performance of late gadolinium enhancement in included studies. CI,
confidence interval
Fig. 4 Summary receiver operator characteristics (SROC) of late gadolinium enhancement on summary estimates of sensitivity and specificity.
AUC, area under the curve; SE, standard error
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showed that the diagnostic accuracy increased with a
summary sensitivity of 85 % and a summary specificity
of 92 %. In terms of the heart tissue characterization,
LGE can distinguish CA patients from healthy controls
with a summary positive likelihood ratio of 7.481 (95 %
CI: 2.835–19.739). The summary diagnostic odds ratio of
71.945 detected here (95 % CI: 23.552–219.77) indicated
that expressed the test was more accurate in the differen-
tial diagnosis of CMR than other types of diagnosis. In this
way, the values of LR+ and DOR favor of LEG–CMR in
patients with suspected CA before EMB. Heterogeneity
was observed across studies in terms of specificity, but not
sensitivity. This could be partially due to the methodo-
logical quality of involved publications on reference tests
choosing and flow and timing.
AL and ATTR are two types of amyloidosis typically
associated with the heart. ATTR is often underdiagnosed
and can be fatal. It also has particular variants in specific
ethnic populations, which makes diagnosing and typing
both necessary and challenging. Recently, several studies
have reported that the new CMR techniques have better
diagnostic accuracy in demonstrating the range of struc-
tural and functional changes in different types of CA
[27]. T1 mapping, a new technique measuring myocar-
dial intrinsic signal, was found to diagnose AL and
ATTR very accurately [28, 29]. Native T1 levels were
higher in ATTR patients than in controls and the area
under the AUC for ATTR and AL patients with possible
or definite cardiac involvement was 0.85 (95 % CI: 0.79–
0.92) [29]. One study reviewed here evaluated the non-
contrast myocardial T1, and the cut-off of 1020 ms
yielded 92 % accuracy for identifying CA [16]. T1–RT
reported by Hosch also diagnosed CA with a high sensi-
tivity (84 %) and specificity (>89 %) with a cut-off value
of ≥1273 ms [15]. The measurement of extracellular vol-
ume (ECV) measurement is popular in some centers
[30, 31]. ECV is elevated in both AL and ATTR, which
helps the evaluation of amyloid burden. It is also ele-
vated in patients where routine examinations, including
LGE, indicated no heart involvement. In the present
systematic review, one study analyzed the myocardial
signal intensity decay (SID) at the subendocardial level
after gadolinium injection, showing a greater accuracy
(96 %) and sensitivity (98 %) for CA assessment than
LGE with a 269 HB threshold [21]. T1 values were
higher in AL amyloid than in ATTR, but ECV was
higher in ATTR [12]. This suggests that combined T1
and ECV techniques may attach more diagnostic accur-
acy to patients with cardiac involvement, quantify the
amyloid burden to evaluate the pathologic conditions,
and distinguish types of CA to help clinicians select the
most appropriate treatment for each patient. When LGE
combine with these advanced techniques, CMR could be
a main technique for the diagnosis of patients with po-
tential CA.
The current review has some limitations, which should
be taken into consideration. The main one is the small
number of studies included, which restricted deep ex-
ploration of potential sources of heterogeneity. The sec-
ond limitation is that the typical amyloid LGE pattern
varies across different series. Localized enhancement,
diffuse transmural or patchy LGE enhancement was re-
ported in different studies. In this review, only three
studies described the diffuse, global subendocardial en-
hancement pattern as the amyloid pattern. The third
limitation is that not all of the studies used the same ref-
erence tests. Not all patients underwent the same refer-
ence tests, introducing selection bias in the final results.
Despite these limitations, the current work can present
the current state of diagnostic tests of CMR for CA,
which may help medical workers choose diagnostic
methods efficiently and effectively.
Conclusion
The current work indicates that the LGE is more accurate
in the diagnosis of CA, which makes it valuable in the de-
tection of amyloid deposit. However, when considering
clinical cost-effectiveness and patients with claustropho-
bia, implanted cardiac devices and renal failure, CMR ap-
plication value in CA needs further investigation.
Fig. 5 Forest plot presenting the pooled diagnostic odds ratio of late gadolinium enhancement. CI, confidence interval
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